Clinical Trial

Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-11.
Status change: Not Yet Recruiting → Recruiting 2026-03-24
Trial Details
NCT Number NCT07353671
Lead Sponsor West China Hospital
Conditions Radiation-induced Dermatitis
Enrollment 60 participants
Start Date 2026-03-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-25